Gadoterate meglumine
Clariscan, Dotarem, Gadoterate Meglumine (gadoterate meglumine) is a small molecule pharmaceutical. Gadoterate meglumine was first approved as Dotarem on 2013-03-20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Clariscan, Dotarem, Gadoterate meglumine
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clariscan | ANDA | 2024-09-17 |
| dotarem | New Drug Application | 2025-03-14 |
| gadoterate meglumine | ANDA | 2025-04-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9575 | Injection, gadoterate meglumine, 0.1 ml |
Clinical
Clinical Trials
81 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | 2 | 1 | 2 | 6 |
| Lymphatic metastasis | D008207 | EFO_1001364 | — | 1 | 1 | 1 | 1 | 3 | 6 |
| Magnetic resonance imaging | D008279 | — | — | — | — | — | 2 | 3 | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | 1 | 1 | 1 | 4 |
| Renal insufficiency | D051437 | — | N19 | 1 | 1 | — | 2 | 1 | 4 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | 1 | 2 | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | 1 | 2 | 3 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | 2 | — | 2 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | 2 | — | 2 |
| Breast diseases | D001941 | — | N60-N65 | 1 | — | — | 1 | — | 2 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 1 | — | 1 | 4 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 1 | 1 | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | 1 | — | 1 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | 1 | — | 1 | 3 |
| Body weight | D001835 | EFO_0004338 | — | — | — | 1 | — | 1 | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 2 | — | — | 2 |
| Central nervous system diseases | D002493 | — | G96.9 | — | — | 2 | — | — | 2 |
| Cerebral arterial diseases | D002539 | EFO_1000859 | — | — | — | 2 | — | — | 2 |
| Rectal neoplasms | D012004 | — | — | — | 1 | 1 | — | — | 2 |
| Aneurysm | D000783 | — | I72.9 | — | 1 | 1 | — | 1 | 2 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine cervical neoplasms | D002583 | — | — | 2 | 2 | — | — | 1 | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 1 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | 1 | 2 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 1 | — | — | 1 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 1 | — | — | 1 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | 1 | 1 | — | — | — | 2 |
| Local anesthesia | D000772 | — | — | 1 | 1 | — | — | — | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | 1 | 2 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | 1 | 2 |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | 1 | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | 1 | 2 |
| Sclerosis | D012598 | — | — | 1 | — | — | — | 1 | 2 |
| Fibroadenoma | D018226 | — | — | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | 1 | — | — | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | — | 1 |
| Infarction | D007238 | EFO_0009463 | — | 1 | — | — | — | — | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | 1 | — | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 2 | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 2 | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 2 | 2 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 2 | 2 |
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | — | — | — | — | 1 | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | — | — | 1 | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 1 | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 1 | 1 |
| Myocardial perfusion imaging | D055414 | — | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Show 26 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gadoterate meglumine |
| INN | _ |
| Description | Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.
|
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 72573-82-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2219415 |
| ChEBI ID | 73727 |
| PubChem CID | 158536 |
| DrugBank | DB09132 |
| UNII ID | L0ND3981AG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,869 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clariscan, Dotarem, Gadoterate meglumine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,307 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use